Related Experiment Videos
Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary
1University of Connecticut School of Medicine and Hartford Hospital, 06102, USA.
Insights
For non-ST-segment elevation acute coronary syndrome, a conservative, ischemia-guided strategy with aggressive medical therapy is recommended. This approach avoids routine invasive procedures, potentially improving patient outcomes and reducing harm, especially for low-risk individuals.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Coronary Syndromes
Background:
- A debate exists regarding the optimal treatment strategy for non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
- The core issue is whether risk stratification should be anatomy-driven or ischemia-driven.
Purpose of the Study:
- To evaluate the efficacy of routine invasive versus conservative strategies in NSTE-ACS patients.
- To recommend an optimal treatment approach based on current evidence.
Main Methods:
- Review of existing clinical trial data, including the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) trial.
- Analysis of outcomes associated with early routine invasive (cardiac catheterization within 24 hours) versus conservative (ischemia-guided) strategies.
Main Results:
- An early routine invasive strategy has not demonstrated improved outcomes in NSTE-ACS.
- The VANQWISH trial indicated worse outcomes in the first year for aggressively treated patients compared to a conservative strategy.
- Conservative management involves intensive medical therapy and interventions only when indicated by ischemia.
Conclusions:
- A conservative, ischemia-guided strategy with aggressive medical therapy is recommended for NSTE-ACS.
- This approach includes intensive antiplatelet, antithrombotic, and anti-ischemic therapies.
- Future research may refine risk stratification to tailor early invasive therapy to high-risk patients, avoiding potential harm in low-risk individuals.
Abstract:
A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non-ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or "drive-through" strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non-ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.